Jeff Evanson - 17 Apr 2023 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role
Chief Commercial Officer
Signature
/s/ Lawrence Kenyon, Attorney-in-Fact
Issuer symbol
OTLK
Transactions as of
17 Apr 2023
Transactions value $
$0
Form type
4
Filing time
19 Apr 2023, 17:41:00 UTC
Previous filing
24 Jan 2023
Next filing
11 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OTLK Stock Option (Right to Buy) Award $0 +192K $0.00 192K 17 Apr 2023 Common Stock 192K $1.08 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on April 17, 2024, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances.